Comparing surgery and medications for treating Lennox-Gastaut syndrome
Official title: Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome - PCORI
Run by Ann & Robert H Lurie Children's Hospital of Chicago · NCT05374824 · Data updated 2026-11-12
This study is testing whether surgery or extra medications work better for people with Lennox-Gastaut syndrome to help reduce seizures and improve their daily lives.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 26 Years |
| Sex | All |
| Enrollment | 4680 (estimated) |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago Academic / other |
| Locations | 4 sites (Chicago, Illinois and 3 other locations) |
| Status | Recruiting |
| Started | April 1, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 6, 2026 |
| Trial ID | NCT05374824 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with Lennox-Gastaut syndrome who have medical records at participating pediatric centers.
✕Probably not a fit
Patients without a diagnosis of Lennox-Gastaut syndrome will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to compare the effectiveness of palliative surgery versus additional anti-seizure medications in patients with Lennox-Gastaut syndrome, a severe form of epilepsy. It will assess how these treatment options impact the frequency of seizure-related emergency healthcare utilization and the functional abilities of patients. The study will gather data from 18 PCORnet sites, focusing on variations in treatment patterns based on patient demographics and characteristics. By analyzing these approaches, the study seeks to provide valuable insights for parents and physicians in making informed treatment decisions.
Why it matters
Potential benefit: If successful, this study could help identify the most effective treatment approach for reducing seizures and improving the quality of life for patients with Lennox-Gastaut syndrome.
How similar studies have gone: While there is strong evidence supporting the effectiveness of both treatment pathways, this study is novel as it seeks to directly compare their effectiveness in a systematic way.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with the diagnosis of Lennox Gastaut syndrome with medical records at the seven plus eleven pediatric centers Exclusion Criteria: Patients without Lennox Gastaut Syndrome
Where it's running
-
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States Recruiting -
C.S. Mott Children's Hospital
Ann Arbor, Michigan, United States Recruiting -
St. Louis Children's Hospital
St Louis, Missouri, United States Recruiting -
Nationwide Children's
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: Sandi Lam, MD MBA — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Sandi Lam, MD MBA
- Email: slam@luriechildrens.org
- Phone: 312 227 4220
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing BMB-101 for Absence Epilepsy and Related Conditions
This study is testing a new treatment called BMB-101 to see if it can help reduce seizures in people with Absence Epilepsy and related conditions.
-
Evaluating Carisbamate for Seizures in Lennox Gastaut Syndrome
This study is testing if a new medication called carisbamate can help reduce drop seizures in people aged 4 to 55 with Lennox Gastaut Syndrome.
-
Evaluating clemizole HCl for treating Lennox-Gastaut syndrome
This study is testing if clemizole HCl can help reduce seizures and improve the lives of people with Lennox-Gastaut syndrome, including children and adults.
-
Adaptive deep brain stimulation for children with Lennox–Gastaut syndrome
This trial will test adaptive deep brain stimulation using the Picostim device to try to reduce seizures in children aged 5–14 with Lennox–Gastaut syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.